Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies

References

• Person AK, Kontoyiannis DP, Alexander DP. Fungal infections in transplant and oncology patients. Infect Dis Clin North Am 2010; 24: 439–459.
   PubMed Web of Science ®Google Scholar
• De la Rosa GR, Champlin RE, Kontoyiannis DP. Risk factors for the development of invasive fungal infections in allogenic blood and marrow transplant recipients. Transpl Infect Dis 2002; 4: 2–9.
   Google Scholar
• Sipsas NV, Kontoyiannis DP. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies. Clin Infect Dis 2006; 42: 1584–1591.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Sieniawski M, Reuter S, . Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. Int J Antimicrob Agents 2009; 34: 446–450.
   PubMed Web of Science ®Google Scholar
• El-Cheikh J, Faucher C, Furst S, . High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2007; 39: 301–306.
   PubMed Web of Science ®Google Scholar
• Perfect JR, Klotman ME, Gilbert CC, . Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165: 891–897.
   PubMed Web of Science ®Google Scholar
• Bodey GP, Anaissie EJ, Elting LS, . Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994; 73: 2009.
   Web of Science ®Google Scholar
• Wolff SN, Fay J, Stevens D, . Fluconazole vs. low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000; 25: 853–859.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Mohty M, Faucher C, . Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31: 135–141.
   PubMed Web of Science ®Google Scholar
• Tollemar J, Ringden O, Andersson S, . Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12: 577–582.
   PubMed Web of Science ®Google Scholar
• Kelsey SM, Goldman JM, McCann S, . Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomized, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23: 163–168.
   PubMed Web of Science ®Google Scholar
• Gubbins PO, Amsden JR, McConell SA, Anaissie EJ. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or a daily dose (1 mg/kg) in peripheral stem cell transplant patients. Antimicrob Agents Chemother 2009; 53: 3664–3674.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, . Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG). Clin Infect Dis 2008; 46: 1813–1821.
   PubMed Web of Science ®Google Scholar
• Bellomo R, Ronco C, Kellum JA, . Acute renal failure definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204–212.
   PubMed Web of Science ®Google Scholar
• Segal BH, Herbrecht R, Stevens DA, . Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clin Infect Dis 2008; 47: 674–683.
   PubMed Web of Science ®Google Scholar
• Segal BH, Almyroudis NG, Battiwalla M, . Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplants recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 2007; 44: 402–409.
   PubMed Web of Science ®Google Scholar
• Mele L, Pagano L, Equitani F, Leona G. Case reports. Secondary prophylaxis with liposomal amphotericin B after invasive aspergillosis following treatment with haematological malignancy. Mycoses 2001; 44: 201–203.
   PubMed Web of Science ®Google Scholar
• Sevilla J, Hernandez-Maraver D, Aquado MJ, . Autologous peripheral blood stem cell transplant in patients previously diagnosed with invasive aspergillosis. Ann Hematol 2001; 80: 456–459.
   PubMed Web of Science ®Google Scholar
• Nosari A, Oreste P, Cairoli R, . Invasive aspergillosis in haematological malignancies: clinical findings and management for intensive chemotherapy completion. Am J Hematol 2001; 68: 231–236.
   PubMed Web of Science ®Google Scholar
• Tedeshi A, Montillo M, Cairoli M, . Prior invasive pulmonary and cerebellar mucormycosis is not a primary contraindication to perform an autologous stem cell transplantation in leukemia. Leuk Lymphoma 2002; 43: 657–659.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Maury S, Pautas S, . Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004; 33: 943–948.
   PubMed Web of Science ®Google Scholar
• Kruger WH, Rüssmann B, de Wit M, . Haemopoietic cell transplantation of patients with history with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B. Acta Haematologica 2005; 113: 104–108.
   PubMed Web of Science ®Google Scholar
• Vaidya SJ, Ortin M, Loperz-Duarte M, . Haemopoietic progenitor cell transplantation in patients with previous history of invasive fungal infection. Leuk Lymphoma 2005; 46: 1143–1150.
   PubMed Web of Science ®Google Scholar
• Nosari A, Ravini M, Cairoli R, . Surgical resection of persistent pulmonary fungus nodules and secondary prophylaxis are effective in preventing fungal relapse in patients receiving chemotherapy or bone marrow transplantation for leukemia. Bone Marrow Transplant 2007; 39: 631–635.
   PubMed Web of Science ®Google Scholar
• De Fabritis P, Spagnoli A, Di Bartolomeo P, . Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogenic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 2007; 40: 245–249.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bohme A, Reichert A, . Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother 2008; 61: 939–946.
   PubMed Web of Science ®Google Scholar
• Zhang P, Song A, Wang S, . Hematopoietic SCT in patients with history of invasive fungal infection. Bone Marrow Transplant 2009; 43: 533–537.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Rovira M, Maertens J, . Voriconazole for secondary prophylaxis of invasive fungal infections in allogenic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95: 1762–1768.
   PubMed Web of Science ®Google Scholar